Author:
d’Andrea Giacomo,Miuli Andrea,Pettorruso Mauro,Cavallotto Clara,Marrangone Carlotta,Cocco Alessio,De Filippis Sergio,Martiadis Vassillis,Andriola Ileana,Barlati Stefano,Vita Antonio,Dell'Osso Bernardo Maria,Sensi Stefano L.,Di Lorenzo Giorgio,Martinotti Giovanni
Reference24 articles.
1. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: an updated analysis of efficacy and tolerability;Adair;J. Affect. Disord.,2023
2. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder;Bang-Andersen;J. Med. Chem.,2011
3. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study;Chiappini;Eur. Neuropsychopharmacol.,2023
4. Emotional blunting in patients with depression. Part II: relationship with functioning, well-being, and quality of life;Christensen;Ann. Gen. Psychiatry,2022
5. Esketamine in Treatment Resistant Depression: A Study Protocol for a Retrospective, Real-life, Multicentric Study;D’Andrea,2022